GlassScriptPhysician profile
Rena C Dearment
NPI 1235197971
$104,116.11
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $32K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24,240.07 | 2019-2020 | |
| Abbott Laboratories | $19,996.11 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,051.50 | 2019-2020 | |
| Lilly USA, LLC | $17,389.91 | 2019-2020 | |
| Amarin Pharma, INC. | $16,830.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $5,073.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $650.14 | 2019-2020 | |
| Amgen INC. | $389.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $323.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $275.78 | 2019-2020 | |
| Abbvie INC. | $164.37 | 2019-2020 | |
| Corcept Therapeutics | $148.91 | 2019 | |
| Mannkind Corporation | $92.32 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $78.11 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $74.69 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $65.77 | 2019-2020 | |
| Shire North American Group INC | $51.28 | 2019 | |
| Amneal Pharmaceuticals LLC | $46.64 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.02 | 2020 | |
| Xeris Pharmaceuticals, INC. | $31.03 | 2020 | |
| Ibsa Pharma INC. | $17.84 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.58 | 2020 | |
| Intercept Pharmaceuticals, INC. | $16.10 | 2020 | |
| Senseonics, Incorporated | $16.00 | 2019 | |
| Radius Health, INC. | $14.30 | 2019 | |
| Lifescan, INC. | $13.07 | 2020 | |
| Sun Pharmaceutical Industries INC. | $12.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Dearment listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.